ClinicalTrials.gov
ClinicalTrials.gov Menu

Femoral Bone Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01428895
Recruitment Status : Recruiting
First Posted : September 5, 2011
Last Update Posted : February 28, 2018
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:

Bone is a common site of metastasis for a range of malignancies. Bone metastases have the potential to cause significant morbidity including pain, impairment of ambulation and reduced functional independence. Previous research has shown that pathological fractures are observed in 9 to 29 percent of patients with long bone metastases, and a high proportion of these require surgical intervention to relieve pain and restore function.

The goal of this study is to describe the clinical outcomes of patients with femoral metastases at high risk of pathological fracture. Patients referred for treatment of femoral metastases at high risk of fracture will be followed prospectively after undergoing with surgery (± post-operative radiotherapy), or radiotherapy alone. Patient and disease characteristics, ambulatory status and limb function will be documented before treatment. These Clinical outcomes of participants in each treatment group will be measured 6 weeks after treatment, and 3- and 6 months after enrolment, with particular reference to patient-reported outcomes relating to pain, ambulatory status, limb function and quality of life.


Condition or disease Intervention/treatment Phase
Cancer Metastatic Malignant Neoplasm to Femur Risk of Fracture Procedure: Surgery Alone Other: Combined Surgery and Radiation therapy Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Prospective Cohort Study of the Role of Surgery and/or Radiotherapy for Bone Metastases of the Femur at High Risk of Pathological Fracture
Study Start Date : March 2009
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fractures
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Surgery Alone Procedure: Surgery Alone
Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
Active Comparator: Surgery + Radiation Therapy Other: Combined Surgery and Radiation therapy
Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.



Primary Outcome Measures :
  1. To describe the ambulatory status at 3 months by intervention (surgery ± radiotherapy, and radiotherapy alone group) - Ambulatory status [ Time Frame: 6 months ]
    Patient will be assessed at baseline, 6 weeks, 3 months and 6 months


Secondary Outcome Measures :
  1. To describe patterns of management in patients with femoral metastases at high risk of pathological fracture - Perioperative Morbidity and Mortality for surgical patients; pain score and performance status; QOL [ Time Frame: 6 months ]
    Patients will be assessed at baseline, 6 weeks, 3 months and 6 months

  2. To describe patient and disease characteristics of major management groups (surgery ± radiotherapy, radiotherapy alone due to preference, radiotherapy alone due to co-morbid conditions) - Assessment of lower limb function [ Time Frame: 6 months ]
    Patient will be assessed at baseline, 6 weeks, 3 months, and 6 months.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of malignancy other than lymphoma
  • Presence of femoral metastases at high risk of pathologic fracture (Mirels' score 8 or more)
  • At least 18 years of age
  • Able to provide written informed consent
  • Able to participate in follow-up

Exclusion Criteria:

  • Surgical consultation for the purpose of obtaining a tissue/histological diagnosis only, not for treatment
  • Histological diagnosis of lymphoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01428895


Contacts
Contact: Rebecca Wong, MB ChB 416 946 4501 ext 2126 Rebecca.wong@rmp.uhn.on.ca

Locations
Canada, Ontario
Mount Sinai Hospital Recruiting
Toronto, Ontario, Canada, M5G 1X5
Contact: Peter Ferguson, MD    416 586-4800 ext 8687    PFerguson@mtsinai.on.ca   
University Health Network, Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Rebecca Wong, MB ChB    416 946 4501 ext 2126    Rebecca.Wong@rmp.uhn.on.ca   
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Rebecca Wong, MB ChB University Health Network, Princess Margaret Hospital
Principal Investigator: Peter Ferguson, MD Mount Sinai Hospital, Canada

Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT01428895     History of Changes
Other Study ID Numbers: OCREB 09-004
First Posted: September 5, 2011    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018

Keywords provided by University Health Network, Toronto:
Bone Metastases
Femoral Metastases

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes